News | Biogen

October 13, 2021

New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience

Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosing Real-world analysis shows significantly lower risk of relapse for patients treated with TYSABRI ® compared to Ocrevus ® (ocrelizumab) New

October 13, 2021

New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis

October 6, 2021

Biogen to Report Third Quarter 2021 Financial Results October 20, 2021

List View Grid View

May 30, 2019

New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis

Diroximel fumarate significantly reduced disease activity in newly diagnosed relapsing multiple sclerosis (MS) patients and those previously treated with interferons or glatiramer acetate Data show treatment discontinuations due to gastrointestinal (GI) events occurred at a low rate over one year

May 21, 2019

Biogen to Present at Bernstein’s 35th Annual Strategic Decisions Conference

Cambridge, MA , - - Biogen Inc. (Nasdaq: BIIB) announced today that it will present at Bernstein’s 35th Annual Strategic Decisions Conference. The webcast will be live on Thursday, May 30, at 10:00 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at

May 20, 2019

Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation

CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Corporation (TRC Capital) to purchase up to 500,000 shares of Biogen’s common stock at a price of $216.25 per share in cash.

May 15, 2019

Biogen to Host Investor Webcast to Discuss ALS Portfolio on June 5, 2019

Cambridge, Mass. – May 15, 2019 – Biogen (Nasdaq: BIIB) today announced it will host a live webcast and Q&A session to review its portfolio of investigational therapies for the treatment of amyotrophic lateral sclerosis (ALS). The live webcast will begin at 8:00 a.m.

May 14, 2019

Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy

SPINRAZA becomes the first therapy recommended in the United Kingdom for 5q spinal muscular atrophy to treat all age groups, including patients who are pre-symptomatic More than 7,500 individuals have been treated with SPINRAZA worldwide in over 40 countries across the Expanded Access Program,

May 7, 2019

Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS

Updated results support lower risk of PML with extended interval dosing (EID; approximately every six weeks) for TYSABRI ® (natalizumab) in patients in a real-world setting New interim data further support safety and efficacy of Biogen and Alkermes’ investigational treatment, diroximel fumarate, to

May 6, 2019

Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen)

Treatment with SPINRAZA resulted in clinically meaningful improvements in motor-function and survival in individuals with spinal muscular atrophy Treating pre-symptomatic infants with SPINRAZA helped patients in the NURTURE study achieve motor milestones more consistent with normal development More

May 1, 2019

Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)

Tofersen, an antisense oligonucleotide (ASO) that selectively targets the genetic driver of disease, is being studied for the potential treatment of ALS in adults with a confirmed superoxide dismutase 1 (SOD1) mutation Late breaking interim data to be presented at the American Academy of Neurology

May 1, 2019

Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases

Data demonstrate that pre-symptomatic infants with SMA treated with SPINRAZA ® (nusinersen) over three years achieved motor milestones that are more consistent with normal childhood development Late-breaking data expand on safety and exploratory efficacy results of a study investigating tofersen

April 30, 2019

Data Published in Neurology Show that Treatment with SPINRAZA® (nusinersen) Improved Motor Function and Provided Long-Term Benefit for Individuals with Later-Onset Spinal Muscular Atrophy

Patients, aged five up to 19, treated with SPINRAZA over three years demonstrated clinically significant improvements in motor function and stabilization of disease activity One individual gained the ability to walk independently – an achievement that has not been previously observed in untreated